VolitionRX Limited Common Stock (VNRX)
0.5812
0.00 (0.00%)
VolitionRx Ltd is a biotechnology company focused on developing diagnostic tests for detecting a variety of cancers and other diseases through innovative blood-based technologies
The company's primary approach involves utilizing its proprietary Nu.Q platform, which analyzes Nucleosomes—fragments of DNA that can indicate the presence of cancer. By providing accessible and accurate diagnostic tools, VolitionRx aims to enhance early detection and improve patient outcomes in oncology and beyond, ultimately contributing to more effective and personalized healthcare solutions.
Previous Close | 0.5812 |
---|---|
Open | - |
Bid | 0.5800 |
Ask | 0.6400 |
Day's Range | N/A - N/A |
52 Week Range | 0.4301 - 1.100 |
Volume | 0 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 108,957 |
News & Press Releases

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · September 16, 2024

VNRX stock results show that VolitionRX beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024
BioMedNewsBreaks — VolitionRx Limited (NYSE American: VNRX) appoints PharmaVentures for Capture PCR(TM) and Oncology Portfolio Licensing
VolitionRx Limited (NYSE American: VNRX), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, announced the engagement of PharmaVentures Ltd (“PharmaVentures”) to act as an advisor. PharmaVentures will provide strategic advice and transactional support as Volition works towards securing licensing deals with industry leaders for both Nu.Q(R) Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR(TM) – a novel detection method for liquid biopsy in cancer and potentially other diseases.
Via Investor Brand Network · July 10, 2024
BioMedNewsBreaks — VolitionRx Limited (NYSE American: VNRX) Highlights Latest Achievements in Mid-Year Review
VolitionRx Limited (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, has released a mid-year review that highlights significant milestones, such as the expansion of the Nu.Q(R) Vet Cancer Test, which is now available for purchase in 15 countries. Additionally, Volition is engaged in active commercial discussions with significant players in the fields of liquid biopsy and in vitro diagnostics (“IVD”), for sepsis, and oncology.
Via Investor Brand Network · June 28, 2024

ORLANDO, FL / ACCESSWIRE / June 14, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) ("Nexalin") and VolitionRX Limited (NYSE American:VNRX) ("Volition") on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · June 14, 2024

VNRX stock results show that VolitionRX beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 13, 2024
VolitionRx Ltd. (NYSE American: VNRX) Featured in Coverage of the EF Hutton Annual Global Conference
VolitionRx (NYSE American: VNRX) is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Via Investor Brand Network · May 6, 2024

Via Benzinga · April 23, 2024

Via Benzinga · April 23, 2024

VNRX stock results show that VolitionRX met analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 25, 2024

Companies Reporting Before The Bell • Bitcoin Depot (NASDAQBTM) is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million.
Via Benzinga · March 25, 2024

With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year.
Via InvestorPlace · January 18, 2024

Via Benzinga · January 3, 2024

Shares of Trinity Place Holdings Inc. (NYSETPHS) rose sharply in pre-market trading. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan. 31, 2024. Trinity Place shares jumped 80.1% to $0.2056 in pre-market trading.
Via Benzinga · January 3, 2024

Via Benzinga · January 2, 2024

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · November 27, 2023

The Dow Jones closed higher by around 2 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · November 20, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via Benzinga · October 6, 2023

Via Benzinga · September 22, 2023

Gainers MicroAlgo Inc. (NASDAQMLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
Via Benzinga · September 22, 2023

Via Benzinga · September 22, 2023